Conjupri FDA Approval History
Last updated by Judith Stewart, BPharm on July 27, 2020.
FDA Approved: Yes (First approved December 19, 2019)
Brand name: Conjupri
Generic name: levamlodipine maleate
Dosage form: Tablets
Company: CSPC Pharmaceutical Group Limited
Treatment for: High Blood Pressure
Conjupri (levamlodipine maleate) is a calcium channel blocker indicated for the treatment of hypertension.
Development timeline for Conjupri
|Dec 20, 2019||Approval FDA Approves Conjupri (levamlodipine maleate) for the Treatment of Hypertension|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.